Look the FDA simply said "appears to be sufficient" for resubmission. There is no way that they could determine whether it is sufficient to grant approval or make a decision about an adult trial until after the submission has been examined. Posters here constantly overstate the position, but that's understandable given that SI does the same.
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-258
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.025(1.86%) |
Mkt cap ! $1.507B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.35 | $1.31 | $2.699M | 2.040M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34995 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 10374 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |